Global Human Insulin Drugs and Delivery Devices Market Segmentation, By Product (Human Insulin (HI) Drugs, Human Insulin (HI) Delivery Devices), Drug (Insulin Analogs and Biosimilar, Long-Acting Biosimilar, Rapid-Acting Biosimilar, Premixed Biosimilar, Human Insulin Biologics, Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics), Delivery Device (Syringes, Pens, Disposable Pens, Reusable Pens, Pen Needles, Standard Pen Needles, Safety Pen Needles), Application (Type I Diabetes, Type II Diabetes), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2031.
Human Insulin Drugs and Delivery Devices Market Analysis
In recent years, the market of human insulin drugs and delivery devices is anticipated to grow rapidly during the forecast period. Diabetes is a condition caused by poor lifestyle choices. With the rise in global population, the disease's prevalence has skyrocketed. Insulin is required by around 100 million people worldwide, including all patients with Type 1 diabetes and between 10% and 25% of people with Type 2 diabetes. Hence, the demand for human insulin drugs and delivery devices is increasing in the market.
Human Insulin Drugs and Delivery Devices Market Size
Global human insulin drugs and delivery devices market size was valued at USD 50.21 billion in 2023 and is projected to reach USD 94.67 billion by 2031, with a CAGR of 8.25% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes
|
Human Insulin Drugs and Delivery Devices Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Teva Pharmaceutical Industries Ltd. (Jerusalem), Bayer (Germany), EUROGINE (Spain), CooperSurgical Inc. (US), Pfizer Inc. (US), HLL Lifecare Limited (Thiruvananthapuram), OCON Medical Ltd. (Israel), Prosan International BV (Netherlands), Melbea Innovations (Hungary), Allergan, Merck & Co., Inc. (US), DKT International (US), Medisafe Distribution Inc. (Canada), Medicines360 (US), Pregna International Limited (India), and Egemen International (Turkey), among others
|
Human Insulin Drugs and Delivery Devices Market Definition
Insulin is a protein hormone that assists people whose bodies cannot make enough insulin control their blood sugar levels. Insulin increases glucose absorption into fatty tissues and muscles, lowering blood glucose levels. It can be injected into the buttocks, the back of the arms, the abdomen, or the legs. Furthermore, insulin not only aids in the management of diabetes but also aids in the treatment of acute complications such as hyperosmolar hyperglycemia and diabetic ketoacidosis. Insulin syringes, insulin pumps, insulin pens, insulin inhalers, and insulin jet injectors are some of the devices that help deliver insulin to the patient's body.
Human Insulin Drugs and Delivery Devices Market Dynamics
Drivers
- Increasing prevalence of diabetes
The rising prevalence of diabetes, mainly type 2 diabetes, is a primary driver of the growth of human insulin drugs and delivery devices. Changing dietary patterns and sedentary lifestyle are the factors that will influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of human insulin drugs and delivery devices market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the human insulin drugs and delivery devices market. Additionally, high disposable income and favorable reimbursement scenario will expand human insulin drugs and delivery devices market. Along with this, the rising geriatric population and advancement in insulin device design will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the growth of human insulin drugs and delivery devices. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of human insulin drugs and delivery devices during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the manufacturing of delivery devices will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market of human insulin drugs and delivery devices. Additionally, strict regulations and reforms for the approval of products and the dearth of awareness among people will act as restrain and further impede the market growth rate during the forecast period of 2024-2031.
This human insulin drugs and delivery devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the human insulin drugs and delivery devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Human insulin drugs and delivery devices market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, and adherence rates are some data variables available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Human Insulin Drugs and Delivery Devices Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency.
The supply chain for the raw materials needed to make human insulin medicines and delivery devices has been interrupted in numerous countries as a result of COVID-19. Furthermore, the market for human insulin medications and delivery devices is shrinking as a result of the outbreak, as makers of these drugs and devices have restricted production. As a result, COVID 19 is projected to significantly influence the market for human insulin medicines and delivery systems.
Human Insulin Drugs and Delivery Devices Market Scope
The human insulin drugs and delivery devices market is segmented on the basis of product, application, drug, delivery device, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Human Insulin (HI) Drugs
- Human Insulin (HI) Delivery Devices
Drug
- Insulin Analogs and Biosimilar
- Long-Acting Biosimilar
- Rapid-Acting Biosimilar
- Premixed Biosimilar
- Human Insulin Biologics
- Short-Acting Biologics
- Intermediate-Acting Biologics
- Premixed Biologics
Application
- Type I Diabetes
- Type II Diabetes
Delivery Device
- Syringes
- Pens
- Disposable Pens
- Reusable Pens
- Pen Needles
- Standard Pen Needles
- Safety Pen Needles
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Human Insulin Drugs and Delivery Devices Market Regional Analysis
The Human insulin drugs and delivery devices market is analyzed and market size insights and trends are provided by country, product, application, drug, delivery device, end-users and distribution channel as referenced above.
The countries covered in the Human insulin drugs and delivery devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America and Europe dominate the human insulin drugs and delivery devices market because of the growing prevalence of diabetes in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Human Insulin Drugs and Delivery Devices Market Share
The human insulin drugs and delivery devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to human insulin drugs and delivery devices market.
Human Insulin Drugs and Delivery Devices Market Leaders Operating in the Market Are:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Biocon (India)
- Boehringer Ingelheim International GmbH. (Germany)
- Medtronic (Ireland)
- Ypsomed AG (Switzerland)
- Julphar (UAE)
- Albireo Pharma, Inc. (U.S.)
- CeQur Simplicity (Switzerland)
- BD (U.S.)
- B. Braun SE (Germany)
- Novo Nordisk A/S (Denmark)
- WOCKHARDT (India)
SKU-